Tumor-infiltrating Lymphocytes Market, By Component (Natural Killer Cells and T-Cells), By Anatomy, By End User, By Application, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV4915
|
Published Date
March 2026
|
Pages
387
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Tumor-infiltrating Lymphocytes Market size was valued at US$12,801.85 Million in 2025, expanding at a CAGR of 12.23% from 2026 to 2033.
Tumor-infiltrating lymphocytes (TILs) are immune cells, primarily T cells, that migrate into and reside within tumor tissues, where they play a vital role in the body’s anti-tumor immune response. These cells help recognize and attack cancer cells, contributing to tumor suppression and influencing patient prognosis. TILs are extensively studied and applied in immunotherapy research, adoptive cell transfer therapies, and personalized cancer treatments to enhance the effectiveness of immune-based interventions. By improving tumor recognition, cytotoxic activity, and immune memory, TILs support more effective therapeutic outcomes. Additionally, they play a key role in advancing modern cancer treatment strategies and enabling the development of targeted, durable, and patient-specific immunotherapies. For instance, according to the U.S. National Cancer Institute, a part of the National Institutes of Health, global cancer research funding supported by public institutions has significantly increased in recent years, with billions of dollars allocated annually toward immunotherapy and cell-based treatments, including TIL-based approaches.
Tumor-infiltrating Lymphocytes Market- Market Dynamics
Increasing Adoption of TIL-Based Therapies
The adoption of Tumor-Infiltrating Lymphocyte (TIL) therapies involves incorporating this advanced form of cellular immunotherapy into standard oncology treatment protocols, enhancing how cancer care is delivered and managed. In the treatment of solid tumors, TIL therapy supports critical steps such as immune cell harvesting, ex vivo expansion, and personalized reinfusion. This approach enables oncologists to provide timely cellular treatments, streamline complex manufacturing processes, and improve both patient outcomes and quality of life.
Ongoing advancements in cell therapy, coupled with supportive regulatory frameworks, are improving treatment efficacy and expanding patient access. These factors are collectively driving the adoption of TIL therapies and fostering innovation in the field of personalized cancer immunotherapy. For example, in January 2025, the Annals of Oncology reported that adoptive cell therapy using TILs demonstrated promising clinical outcomes in patients with advanced melanoma. Across evaluated studies, objective response rates ranged from approximately 30% to 50%, indicating meaningful clinical activity in heavily pretreated patients. The analysis also noted that combining TIL therapy with high-dose interleukin-2 is increasingly being investigated to boost antitumor immune responses, underscoring the growing clinical adoption and research interest in TIL-based immunotherapies.
Tumor-infiltrating Lymphocytes Market- Segmentation Analysis:
The Global Tumor-infiltrating Lymphocytes Market is segmented on the basis of Component, Anatomy, End User, Application, and Region.
The tumor-infiltrating lymphocytes (TIL) market is segmented by component into T-cells and natural killer (NK) cells. The T-cell segment accounts for a significant share due to its critical role in recognizing and attacking cancer cells within the tumor microenvironment. T-cells serve as the body’s primary defense by identifying and eliminating harmful cells, including cancerous cells. In TIL therapy, T-cells are harvested from a patient’s tumor, expanded ex vivo, and reinfused to strengthen the immune system’s ability to combat cancer. This approach enhances the body’s natural defenses and improves the efficacy of immunotherapy. T-cell-based therapies are central to the development of personalized cancer treatments, allowing more targeted and effective approaches for specific cancer types. For example, in December 2024, the U.S. government reported that immune effector cell therapies, including CAR-T cells and TIL therapies, have gained significant attention as advanced cancer treatments. By April 2023, six CAR-T cell therapies had received approval from the U.S. Food and Drug Administration (FDA) for treating hematologic malignancies such as leukemia, B-cell lymphomas, and multiple myeloma. Additionally, TIL therapy reached a major milestone with the FDA approval of lifileucel (Amtagvi) in 2024 for advanced melanoma, reflecting growing clinical adoption of T-cell–based immunotherapies and continued advancements in personalized oncology.
The market is also segmented based on T-cell anatomy, including CD3, CD4, CD8, CD16, CD56, CD57, and FOXP3 subsets. The CD3 segment holds a prominent share due to its central role in T-cell activation and initiation of immune responses against tumors. CD3 is a surface protein on T-cells that enables the recognition of cancer cells and triggers immune activation. Understanding T-cell subsets allows researchers and clinicians to isolate, expand, and reinfuse specific immune cells, such as CD8+ cytotoxic T-cells or FOXP3+ regulatory T-cells, making TIL therapies more precise and effective. For instance, in March 2025, the Melanoma Focus Organization reported that TIL therapy is emerging as a promising investigational treatment for advanced melanoma, with growing clinical activity worldwide. By early 2025, over 40 global clinical trials involving TIL therapy were ongoing, demonstrating expanding research and patient access. Key investigational products, including lifileucel, have shown objective response rates of approximately 30% to 50% in recent phase II studies, highlighting their potential in refractory and treatment-resistant melanoma cases. These developments underscore the accelerating adoption of TIL-based immunotherapies and the broader shift toward immune-focused, personalized oncology treatments.
Tumor-infiltrating Lymphocytes Market- Geographical Insights
The Tumor-Infiltrating Lymphocytes (TIL) market shows distinct regional variations, influenced by differences in healthcare infrastructure, research capabilities, and technology adoption. North America holds a major share, driven by advanced healthcare systems, state-of-the-art research facilities, and strong demand for immunotherapy and personalized cancer treatments, particularly in the United States and Canada. According to the U.S. National Cancer Institute, federal funding for cancer immunotherapy research, including TIL-based therapies, exceeded $1.5 billion in 2023, reflecting government commitment to advancing cellular immunotherapies.
Europe exhibits steady growth, supported by increasing investments in cell and gene therapies, robust regulatory frameworks, and the expansion of clinical trial networks. The Asia-Pacific region is expected to experience significant growth during the forecast period, fueled by large patient populations, rising awareness of cancer immunotherapies, and government initiatives promoting advanced oncology treatments in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are gradually strengthening their presence in the market, supported by expanding healthcare infrastructure, improving access to immunotherapy, and growing awareness of TIL-based cancer treatments. These regional trends highlight the global shift toward personalized and immune-based oncology therapies.
United States Tumor-Infiltrating Lymphocytes Market – Country Insights
The United States TumorInfiltrating Lymphocytes (TIL) market is witnessing steady growth, supported by a well-established healthcare system and strong investment in advanced cancer immunotherapies. Healthcare providers and research institutions are increasingly adopting TIL therapies to improve outcomes for patients with hard-to-treat cancers, such as melanoma. Active participation from leading biotechnology and pharmaceutical companies, combined with supportive government initiatives for cell-based therapies and cancer research funding, continues to drive market expansion.
Additionally, growing emphasis on personalized medicine, improved clinical results, and expanding clinical trial activity are accelerating the adoption of TIL therapies across oncology settings. For example, in March 2025, the U.S. government reported that the global personalized medicine sector was valued at approximately USD550.2billion in 2024 and is projected to reach USD1,302.7billion by 2035, growing at a CAGR of around 8.15%. This growth is driven by advances in genomic technologies, data analytics, and precision treatment approaches that tailor care to individual patient profiles. These trends highlight the increasing demand for personalized medicine as a transformative healthcare strategy that enhances diagnostic accuracy, optimizes treatment efficacy, and supports more individualized patient care.
Tumor-infiltrating Lymphocytes Market- Competitive Landscape:
The Tumor-Infiltrating Lymphocytes (TIL) market is moderately concentrated, with several leading biotechnology and biopharmaceutical companies driving competition. Key players include Autolus Therapeutics PLC, Bellicum Pharmaceuticals, Iovance Biotherapeutics, Pfizer, Inc., and MaxCyte, Inc. These companies focus on developing advanced TIL-based immunotherapies for personalized cancer treatment, emphasizing tumor-specific T-cell expansion, genetic modification, and enhanced anti-tumor efficacy. For instance, in 2024, Iovance Biotherapeutics advanced its TIL therapy pipeline by incorporating next-generation cell engineering techniques, improving tumor targeting and treatment outcomes. Market growth is fueled by rising demand for personalized oncology treatments, increasing investments in immunotherapies, and broader adoption of cell-based therapies. Companies are expanding TIL offerings through advanced manufacturing, scalable production, combination therapies, and clinical collaborations, supporting both oncology needs and overall market development.
Recent Developments:
- In January 2025, CRISPR Therapeutics continued the global rollout of its first approved CRISPR-based gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease and transfusion-dependent beta-thalassemia. Over 65 authorized treatment centers have been activated worldwide, with increasing patient cell collections as the therapy expands its clinical reach, highlighting both the company’s progress and broader momentum in gene-editing therapeutic platforms.
- In April 2024, Celyad Oncology enhanced its multiplex miRNA-based non-gene-edited technology platform by expanding it to a 5-plex system, allowing simultaneous modulation of five target genes in CAR-T cells. This advancement fine-tunes cell function and therapeutic outcomes, representing a technological step forward in CAR-T engineering approaches.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- CAutolus Therapeutics
- Bellicum Pharmaceuticals, Inc.
- Eli Lilly and Company
- Iovance Biotherapeutics, Inc
- Seeking Alpha.
- Cellectis S.A.
- Celyad Oncology SA
- CRISPR Therapeutics AG
- Intellia Therapeutics Inc.
- Unum Therapeutics
- Autolus Therapeutics PLC
- Amgen Inc.
- Gilead Sciences Inc.
- Sorrento Therapeutics Inc.
- BioNTech SE
- Pfizer Inc.
- bluebird bio, Inc.
- Fate Therapeutics
- MaxCyte Inc
- Novartis AG
- Others
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COMPONENT- MARKET ANALYSIS, 2020 - 2033
- Natural Killer Cells
- T-Cells
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY ANATOMY- MARKET ANALYSIS, 2020 - 2033
- FOXP3
- CD56
- CD57
- CD4
- CD3
- CD8
- CD16
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Cancer Research Centers
- Hospitals
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Ovarian Cancer
- Melanoma
- Cervical Cancer
- Other Applications
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Tumor-infiltrating Lymphocytes Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Tumor-infiltrating Lymphocytes Market Snippet by Component
2.1.2. Tumor-infiltrating Lymphocytes Market Snippet by Anatomy
2.1.3. Tumor-infiltrating Lymphocytes Market Snippet by End User
2.1.4. Tumor-infiltrating Lymphocytes Market Snippet by Application
2.1.5. Tumor-infiltrating Lymphocytes Market Snippet by Country
2.1.6. Tumor-infiltrating Lymphocytes Market Snippet by Region
2.2. Competitive Insights
3. Tumor-infiltrating Lymphocytes Key Market Trends
3.1. Tumor-infiltrating Lymphocytes Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Tumor-infiltrating Lymphocytes Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Tumor-infiltrating Lymphocytes Market Opportunities
3.4. Tumor-infiltrating Lymphocytes Market Future Trends
4. Tumor-infiltrating Lymphocytes Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Tumor-infiltrating Lymphocytes Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Tumor-infiltrating Lymphocytes Market Landscape
6.1. Tumor-infiltrating Lymphocytes Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Tumor-infiltrating Lymphocytes Market – By Component
7.1. Overview
7.1.1. Segment Share Analysis, By Component, 2025&2033 (%)
7.1.2. Natural Killer Cells
7.1.3. T-Cells
8. Tumor-infiltrating Lymphocytes Market – By Anatomy
8.1. Overview
8.1.1. Segment Share Analysis, By Anatomy, 2025&2033 (%)
8.1.2. FOXP3
8.1.3. CD56
8.1.4. CD57
8.1.5. CD4
8.1.6. CD3
8.1.7. CD8
8.1.8. CD16
9. Tumor-infiltrating Lymphocytes Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2025&2033 (%)
9.1.2. Clinics
9.1.3. Cancer Research Centers
9.1.4. Hospitals
10. Tumor-infiltrating Lymphocytes Market – By Application
10.1. Overview
10.1.1. Segment Share Analysis, By Anatomy, 2025&2033 (%)
10.1.2. Ovarian Cancer
10.1.3. Melanoma
10.1.4. Cervical Cancer
10.1.5. Other Applications
11. Tumor-infiltrating Lymphocytes Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025&2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Tumor-infiltrating Lymphocytes Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Tumor-infiltrating Lymphocytes Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Tumor-infiltrating Lymphocytes Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Tumor-infiltrating Lymphocytes Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Tumor-infiltrating Lymphocytes Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Component, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Anatomy, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Tumor-infiltrating Lymphocytes Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. CAutolus Therapeutics
12.2.2. Bellicum Pharmaceuticals, Inc.
12.2.3. Eli Lilly and Company
12.2.4. Iovance Biotherapeutics, Inc
12.2.5. Seeking Alpha.
12.2.6. Cellectis S.A.
12.2.7. Celyad Oncology SA
12.2.8. CRISPR Therapeutics AG
12.2.9. Intellia Therapeutics Inc.
12.2.10. Unum Therapeutics
12.2.11. Autolus Therapeutics PLC
12.2.12. Amgen Inc.
12.2.13. Gilead Sciences Inc.
12.2.14. Sorrento Therapeutics Inc.
12.2.15. BioNTech SE
12.2.16. Pfizer Inc.
12.2.17. bluebird bio, Inc.
12.2.18. Fate Therapeutics
12.2.19. MaxCyte Inc
12.2.20. Novartis AG
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- CAutolus Therapeutics
- Bellicum Pharmaceuticals, Inc.
- Eli Lilly and Company
- Iovance Biotherapeutics, Inc
- Seeking Alpha.
- Cellectis S.A.
- Celyad Oncology SA
- CRISPR Therapeutics AG
- Intellia Therapeutics Inc.
- Unum Therapeutics
- Autolus Therapeutics PLC
- Amgen Inc.
- Gilead Sciences Inc.
- Sorrento Therapeutics Inc.
- BioNTech SE
- Pfizer Inc.
- bluebird bio, Inc.
- Fate Therapeutics
- MaxCyte Inc
- Novartis AG
- Others
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COMPONENT- MARKET ANALYSIS, 2020 - 2033
- Natural Killer Cells
- T-Cells
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY ANATOMY- MARKET ANALYSIS, 2020 - 2033
- FOXP3
- CD56
- CD57
- CD4
- CD3
- CD8
- CD16
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Cancer Research Centers
- Hospitals
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Ovarian Cancer
- Melanoma
- Cervical Cancer
- Other Applications
GLOBAL TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
